Medinet CoTSE:2370 41 Days Payable is 33.00 as of Mar. 2026, which is 1% below its 10-year median of 33.40. GuruFocus rates TSE:2370 with a GF Score™ of 41/100 and a GF Value™ of 円41.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 701 Biotechnology companies, Medinet Co ranks worse than 83.02% on this metric.
Medinet Co's average Accounts Payable for the
three
months ended in Mar. 2026 was 円50.3 Mil. Medinet Co's Cost of Goods Sold for the
three
months ended in Mar. 2026 was 円139.2 Mil.
Hence, Medinet Co's Days Payable for the
three
months ended in Mar. 2026 was 33.00.
The historical rank and industry rank for Medinet Co's Days Payable or its related term are showing as below:
TSE:2370'
s Days Payable Range Over the Past 10 Years
Min: 25.68 Med: 33.4 Max: 85.33
Current: 26.76
During the past 13 years, Medinet Co's highest Days Payable was 85.33. The lowest was 25.68. And the median was 33.40.
TSE:2370's Days Payable is ranked worse than 83.02% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs TSE:2370: 26.76
Medinet Co's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (33.00).
It may suggest that Medinet Codelayed paying its suppliers.
Medinet Co Days Payable Related Terms
Medinet Co Days Payable Historical Data
* Premium members only.
The historical data trend for Medinet Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Medinet Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Medinet Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medinet Co's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinet Co (TSE:2370) has a Days Payable of 33.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medinet Co and its competitors. This is near median its historical median of 33.40. Over the past decade, Medinet Co's Days Payable has ranged from 25.68 to 85.33. According to the industry distribution chart, Medinet Co ranks #582 out of 701 companies in the Biotechnology industry, placing it in the top 83%.
Is Medinet Co's Days Payable too high?
Medinet Co's current Days Payable of 33.00 is near median its 10-year median of 33.40. Over the past 10 years, this metric has ranged from a low of 25.68 to a high of 85.33. The Biotechnology industry median Days Payable is 112.84. Medinet Co's value of 33.00 is 70.8% below this industry median. Based on the distribution chart, Medinet Co ranks #582 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medinet Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #582 out of 701 companies for Days Payable. This places Medinet Co in the lower half of its industry. The industry median Days Payable is 112.84. Medinet Co's value of 33.00 is 70.8% below this benchmark. Historically, Medinet Co's own Days Payable has ranged from 25.68 to 85.33 over the past decade. While the company's 10-year median is 33.40 vs. the industry median of 112.84, Medinet Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinet Co's current Days Payable of 33.00 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medinet Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinet Co's current Days Payable is 33.00, which is near median its own 10-year median of 33.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.74, compared to a current price of 円25.00 — trading 40.1% below its estimated fair value. The current Days Payable is 33.00, which is near median its 10-year median of 33.40 and 70.8% below the Biotechnology industry median of 112.84. Medinet Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Days Payable is 33.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40.1% below its estimated GF Value™ of 円41.74.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
Days Payable: 33.00 (near median its 10-year median of 33.40)
GF Value™: 円41.74 vs. price of 円25.00 (40.1% below fair value)
Industry Position: 70.8% below the Biotechnology median (#582 of 701)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
41GF Score
Get the complete analysis for TSE:2370
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
